French-based biopharmaceutical firm Onxeo has closed enrolment for its Phase III clinical trial (ReLive) of Livatag for the treatment of advanced hepatocellular carcinoma (HCC), a primary liver cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A nanoparticle formulation of doxorubicin, Livatag utilises the firm's Transdrug technology to enable the penetration of the drug into the tumour cell, as well as enhance the exposure of target DNA to the drug.

The trial currently includes a total of 390 randomised patients, of which about 260 are in the Livatag treatment group and the remaining 130 in the comparative group.

Conducted in 11 countries, the ReLive trial is assessing the efficacy of Livatag, administered intravenously in patients with advanced HCC.

Onxeo chief executive officer Judith Greciet said: “Completion of enrolment in ReLive marks a significant milestone for the HCC community.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This is a major step forward in the development of Livatag as a new therapeutic option in a pathology, for which there is a strong need for new treatment."

"This is a major step forward in the development of Livatag as a new therapeutic option in a pathology, for which there is a strong need for new treatment.

"It is also a major achievement for Onxeo, which demonstrates its ability to complete a large international Phase III trial and marks a major value creation catalyst in line with the expected publication of preliminary results in mid-2017."

Livatag aids doxorubicin to bypass the mechanisms of multi-drug resistance developed by tumour cells and accumulates in the liver cells.

To date, the nine reviews on ReLive trial performed by Data Safety and Monitoring Board (DSMB) have indicated a positive safety profile of the drug.

Image: Hepatocellular carcinoma. Photo: courtesy of Ed Uthman/Wikipedia.